Sodium zirconium cyclosilicate for treating hyperkalaemia

Published on 19 Dec 2022
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:                                                                                                           

• Sodium zirconium cyclosilicate 5 g powder for oral suspension for the treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3b to 5 (non-dialysis dependent):

  • who have experienced at least 2 episodes of hyperkalaemia (defined as serum potassium levels of at least 5.5 mmol/L) in the past 12 months, and

  • who are receiving treatment with a renin-angiotensin-aldosterone system (RAAS) inhibitor, or who are indicated for treatment with a RAAS inhibitor but unable to tolerate it due to hyperkalaemia.

Funding status

Sodium zirconium cyclosilicate 5 g powder for oral suspension is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.

MAF assistance does not apply to sodium zirconium cyclosilicate 10 g powder for oral suspension.

Sodium zirconium cyclosilicate for treating hyperkalaemia (Updated 6 Feb 2026) [PDF, 133 KB]

PES Sodium zirconium cyclosilicate for treating hyperkalaemia (Updated 6 Feb 2026) [PDF, 115 KB]